Immunic (IMUX) Change in Accured Expenses (2013 - 2026)

Immunic has disclosed Change in Accured Expenses across 14 years of filings, most recently posting $273000.0 for Q1 2026.

• Change in Accured Expenses for Q1 2026 came in at $273000.0, down 94.21% year-over-year; the trailing twelve-month figure through Mar 2026 was $39000.0 (down 99.35% YoY), and the FY2025 annual result was $4.5 million, up 192.12% from the prior year.
• Change in Accured Expenses came in at $273000.0 for Q1 2026 at Immunic, up from -$398000.0 in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $6.1 million in Q2 2024 to a low of -$6.1 million in Q1 2024.
• The 5-year median for Change in Accured Expenses is $12000.0 (2022), against an average of $79294.1.
• Peak annual rise in Change in Accured Expenses reached 49050.0% in 2023, while the deepest fall reached 3193.44% in 2023.
• Immunic's Change in Accured Expenses stood at $1.5 million in 2022, then tumbled by 500.61% to -$5.9 million in 2023, then climbed by 15.77% to -$4.9 million in 2024, then surged by 91.94% to -$398000.0 in 2025, then soared by 168.59% to $273000.0 in 2026.
• The last three Change in Accured Expenses figures came in at $273000.0 (Q1 2026), -$398000.0 (Q4 2025), and $5.1 million (Q3 2025), per Business Quant data.